PR Newswire Clinical TrialsOriginal article
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
RegulatoryapprovedWAKIXPositive
AI Analysis
Summary
Viatris announced approval of WAKIX (Pitolisant) in Japan for narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome. The first-in-class treatment addresses a significant unmet medical need and expands Viatris' innovative portfolio in the Japanese market.
Outcome Details
Japan's Ministry of Health, Labour and Welfare granted approval for WAKIX (Pitolisant)
Importance:7/10
Sentiment:
0.80
regulatory approvalJapannarcolepsyfirst-in-classsleep disorder
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 16, 2026 10:59 AM